KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma.

Nancy L Bartlett, Uwe Hahn, Won-Seog Kim, Isabelle Fleury, Kamel Laribi, Juan-Miguel Bergua, Krimo Bouabdallah, Nicholas Forward, Fontanet Bijou, David MacDonald, Craig A Portell, Herve Ghesquieres, Grzegorz Nowakowski, Christopher A Yasenchak, Monica Patterson, Linda Ho, Evelyn Rustia, Michelle Fanale, Fei Jie, Jeong-A Kim

J Clin Oncol 43(9) 1061-1072

PMID39772655
PMCIDPMC11936473
DOI10.1200/JCO-24-02242
发表日期2025-01-08
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 5 张 PMC Figure,均未识别为 KM 图:FIG 1.:CONSORT/入组流程图;FIG 2.:森林图/亚组分析图;FIG 3.:森林图/亚组分析图;FIG A1.:非 KM 图;FIG A2.:非 KM 图。
摘要

摘要

PURPOSE: In patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), brentuximab vedotin (BV) as monotherapy or combined with either lenalidomide (Len) or rituximab (R) has demonstrated efficacy with acceptable safety. We evaluated the efficacy and safety of BV + Len + R versus placebo + Len + R in patients with R/R DLBCL. METHODS: ECHELON-3 is a randomized, double-blind, placebo-controlled, multicenter, phase 3 trial comparing BV + Len + R with placebo + Len + R in patients with R/R DLBCL. Patients received BV or placebo once every 3 weeks, Len once daily, and R once every 3 weeks. The primary end point was overall survival (OS), and secondary end points included investigator-assessed progression-free survival (PFS) and objective response rate (ORR). A prespecified interim analysis was performed after 134 OS events, with two-sided P = .0232 as the efficacy boundary. RESULTS: Patients (N = 230) were randomly assigned to receive BV + Len + R (n = 112) or placebo + Len + R (n = 118). Two patients in the placebo arm did not receive treatment. With a median follow-up of 16.4 months, the median OS was 13.8 months with BV + Len + R versus 8.5 months with placebo + Len + R (hazard ratio, 0.63 [95% CI, 0.45 to 0.89]; two-sided P = .009). The median PFS was 4.2 months with BV + Len + R versus 2.6 months with placebo + Len + R (hazard ratio, 0.53 [95% CI, 0.38 to 0.73]; two-sided P < .001). The ORR was 64% ([95% CI, 55 to 73]; two-sided P < .001) with BV + Len + R and 42% (95% CI, 33 to 51) with placebo + Len + R; complete response rates were 40% and 19%, respectively. Treatment-emergent adverse events (AEs) occurred in 97% of patients in both arms. In both arms, the most common treatment-emergent AEs were neutropenia, thrombocytopenia, diarrhea, and anemia. CONCLUSION: BV + Len + R demonstrated a statistically significant survival benefit with a manageable safety profile in heavily pretreated patients with R/R DLBCL.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.Enrollment, random assignment, and follow-up. A total of 339 patients were assessed for eligibility, and 230 patients were randomly assigned to receive BV + Len + R or placebo + Len + R. The intention-to-treat population included all randomly assigned patients, and the safety population included patients who received ≥1 dose of the study treatment. BV, brentuximab vedotin; Len, lenalidomide; R, rituximab.
非 KM Figure
FIG 2.OS in the intention-to-treat population. (A) Shows the Kaplan-Meier estimates of OS in the intention-to-treat population. The median OS was significantly longer with BV + Len + R. Tick marks on the curves indicate censoring of data. (B) Shows a subgroup analysis of OS. a Subgroup with hazard ratio for death of <1. BV, brentuximab vedotin; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; IPI, International Prognostic Index; Len, lenalidomide; NA, not available; OS, overall survival; R, rituximab; R/R, relapsed or refractory.
非 KM Figure
FIG 3.PFS in the intention-to-treat population. (A) Shows the Kaplan-Meier estimates of investigator-assessed PFS in the intention-to-treat population. The median PFS was significantly longer with BV + Len + R. Tick marks on the curves indicate censoring of data. (B) Shows subgroup analysis of PFS. a Subgroup with hazard ratio for disease progression or death of <1. BV, brentuximab vedotin; CAR, chimeric antigen receptor; ECOG PS, Eastern Cooperative Oncology Group performance status; GCB, germinal center B cell; IPI, International Prognostic Index; Len, lenalidomide; PFS, progression-free survival; R, rituximab.
非 KM Figure
FIG A1.PFS in patients with complete or partial response. Kaplan-Meier estimates of investigator-assessed PFS (A) in patients who achieved complete response, and (B) in patients who achieved a partial response. Tick marks on the curves indicate censoring of data. BV, brentuximab vedotin; Len, lenalidomide; NE, not evaluable; PFS, progression-free survival; R, rituximab.
非 KM Figure
FIG A2.DOR in the intent-to-treat population. Kaplan-Meier estimates of DOR in evaluable patients per Lugano classification, 18 as determined by the investigator. (A) DOR (complete or partial) in the intent-to-treat population. (B) Duration of complete response in evaluable patients. (C) Duration of partial response in evaluable patients. Tick marks on the curves indicate censoring of data. BV, brentuximab vedotin; DOR, duration of response; Len, lenalidomide; NE, not evaluable; R, rituximab.
非 KM Figure